-
JAMA Oncology
Original Investigation
May 11, 2023
Oleg Gluz, MD; Ulrike A. Nitz, MD; Matthias Christgen, MD, PhD; Sherko Kuemmel, MD, PhD; Johannes Holtschmidt, MD; Johannes Schumacher, PhD; Andreas Hartkopf, MD; Jochem Potenberg, MD; Kerstin Lüedtke-Heckenkamp, MD; Marianne Just, MD; Christian Schem, MD, PhD; Raquel von Schumann, MD; Cornelia Kolberg-Liedtke, MD, PhD; Christine Zu Eulenburg, PhD; Timo Schinköthe, MD, PhD; Monika Graeser, MD; Rachel Wuerstlein, MD; Ronald E. Kates, PhD; Hans Heinrich Kreipe, MD, PhD; Nadia Harbeck, MD, PhD
online first
JAMA Oncol. 2023; doi: 10.1001/jamaoncol.2023.0646
This randomized clinical trial aims to determine whether neoadjuvant de-escalated chemotherapy is superior to endocrine therapy, both in combination with pertuzumab and trastuzumab, in a highly heterogeneous hormone receptor–positive/ERBB2-positive early breast cancer.
-
JAMA Network Open
Original Investigation
Oncology
May 11, 2023
Jason A. Mouabbi, MD; Akshara Singareeka Raghavendra, MBBS, MS; Roland L. Bassett Jr, MS; Amy Hassan, MD; Debasish Tripathy, MD; Rachel M. Layman, MD
open access
JAMA Netw Open. 2023; 6(5):e2313017. doi: 10.1001/jamanetworkopen.2023.13017
This cohort study of women with hormone receptor–positive metastatic breast cancer treated with targeted therapy in combination with endocrine therapy compares the outcomes for those with low vs no ERBB2 expression.
-
JAMA Oncology
Brief Report
April 27, 2023
Adrienne G. Waks, MD; Esther R. Ogayo, BS; Laia Paré, PhD; Mercedes Marín-Aguilera, PhD; Fara Brasó-Maristany, PhD; Patricia Galván, PhD; Oleguer Castillo, MS; Olga Martínez-Sáez, MD; Ana Vivancos, PhD; Patricia Villagrasa, PhD; Guillermo Villacampa, MSc; Paolo Tarantino, MD; Neelam Desai, MD; Jennifer Guerriero, PhD; Otto Metzger, MD; Nadine M. Tung, MD; Ian E. Krop, MD, PhD; Joel S. Parker, PhD; Charles M. Perou, PhD; Aleix Prat, MD, PhD; Eric P. Winer, MD; Sara M. Tolaney, MD, MPH; Elizabeth A. Mittendorf, MD, PhD
online first
JAMA Oncol. 2023; doi: 10.1001/jamaoncol.2023.0181
This clinical trial examines the ability of the HER2DX assay to predict the likelihood of pathologic complete response in patients with early-stage ERBB2–positive breast cancer who are receiving deescalated neoadjuvant therapy.
-
JAMA Network Open
Original Investigation
Oncology
February 21, 2023
Sung Jun Ma, MD; Jasmin Gill; Olivia Waldman, BSc; Keerti Yendamuri; Cynthia Dunne-Jaffe, BSc; Udit Chatterjee, BBA; Fatemeh Fekrmandi, MD; Rohil Shekher, MD; Austin Iovoli, MD; Song Yao, PhD; Oluwadamilola T. Oladeru, MD, MBA, MA; Anurag K. Singh, MD
open access
JAMA Netw Open. 2023; 6(2):e230179. doi: 10.1001/jamanetworkopen.2023.0179
This cohort study of US women with estrogen receptor (ER)-positive breast cancer examines the association of income levels with 21-gene recurrence scores and survival outcomes.
-
JAMA Oncology
Original Investigation
April 1, 2023
Daniel S. Peiffer, MD, PhD; Fangyuan Zhao, MA; Nan Chen, MD; Olwen M. Hahn, MD; Rita Nanda, MD; Olufunmilayo I. Olopade, MD; Dezheng Huo, MD, PhD; Frederick M. Howard, MD
open access
JAMA Oncol. 2023; 9(4):500-510. doi: 10.1001/jamaoncol.2022.7476
This cohort study uses National Cancer Database data to investigate whether breast cancer with low ERBB2 expression is a clinically distinct subtype compared with breast cancer with no ERBB2 expression, with distinct epidemiological characteristics, prognosis, and response to neoadjuvant chemotherapy.
-
JAMA Network Open
Original Investigation
Oncology
March 30, 2023
Fangyuan Zhao, MA; Minoru Miyashita, MD, PhD; Masaya Hattori, MD; Toshio Yoshimatsu, MS; Frederick Howard, MD; Kristiyana Kaneva, MD, MS; Ryan Jones, MD, PhD; Joshua S. K. Bell, PhD; Gini F. Fleming, MD; Nora Jaskowiak, MD; Rita Nanda, MD; Yonglan Zheng, PhD; Dezheng Huo, MD, PhD; Olufunmilayo I. Olopade, MBBS
open access
JAMA Netw Open. 2023; 6(3):e233329. doi: 10.1001/jamanetworkopen.2023.3329
This cohort study examines whether racial disparities exist in achieving pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and what factors contribute to them among patients with breast cancer.
-
JAMA Network Open
Original Investigation
Oncology
March 30, 2023
Sarah Shubeck, MD, MS; Fangyuan Zhao, MA; Frederick M. Howard, MD; Olufunmilayo I. Olopade, MD; Dezheng Huo, MD, PhD
open access
JAMA Netw Open. 2023; 6(3):e235834. doi: 10.1001/jamanetworkopen.2023.5834
This cohort study examines discrepancies in response to neoadjuvant chemotherapy among patients in differing racial and ethnic groups with breast cancer.
-
JAMA Oncology
Original Investigation
April 1, 2023
Kent F. Hoskins, MD; Gregory S. Calip, PharmD, MPH, PhD; Hsiao-Ching Huang, MPH; Abiola Ibraheem, MD; Oana C. Danciu, MD; Garth H. Rauscher, PhD
JAMA Oncol. 2023; 9(4):536-545. doi: 10.1001/jamaoncol.2022.7705
This retrospective mediation analysis examines the proportion of the Black-White disparity in breast cancer survival from estrogen receptor–positive, axillary node-negative breast cancer that is mediated by adverse social determinants and high-risk tumor biology.
-
JAMA Network Open
Original Investigation
Oncology
April 6, 2023
Xavier Pivot, MD, PhD; Javier Cortés, MD; Diana Lüftner, MD; Gary H. Lyman, MD; Giuseppe Curigliano, MD; Igor M. Bondarenko, MD; Jin-Hee Ahn, MD; Seock-Ah Im, MD; Maria Litwiniuk, MD; Yaroslav V. Shparyk, MD; Gwo Fuang Ho, MD; Nikolay V. Kislov, MD; Marek Wojtukiewicz, MD; Tomasz Sarosiek, MD; Yee Soo Chae, MD; Jin Seok Ahn, MD; Hyerin Jang, DVM; Sujung Kim, BS; Jiwon Lee, MS; YeChan Yoon, PharmD
open access
JAMA Netw Open. 2023; 6(4):e235822. doi: 10.1001/jamanetworkopen.2023.5822
This secondary analysis of a randomized clinical trial compares long-term safety and efficacy of SB3, a trastuzumab biosimilar, with reference trastuzumab for treatment of patients with ERBB2-positive early or locally advanced breast cancer.
-
JAMA Oncology
Original Investigation
March 9, 2023
Tufia C. Haddad, MD; Vera J. Suman, PhD; Antonino B. D’Assoro, MD, PhD; Jodi M. Carter, MD, PhD; Karthik V. Giridhar, MD; Brendan P. McMenomy, MD; Katelyn Santo, BS; Erica L. Mayer, MD, MPH; Meghan S. Karuturi, MD; Aki Morikawa, MD, PhD; P. Kelly Marcom, MD; Claudine J. Isaacs, MD; Sun Young Oh, MD; Amy S. Clark, MD; Ingrid A. Mayer, MD; Khandan Keyomarsi, PhD; Timothy J. Hobday, MD; Prema P. Peethambaram, MD; Ciara C. O’Sullivan, MB, BCh; Roberto A. Leon-Ferre, MD; Minetta C. Liu, MD; James N. Ingle, MD; Matthew P. Goetz, MD
open access
online first
JAMA Oncol. 2023; doi: 10.1001/jamaoncol.2022.7949
This randomized clinical trial examines the effect of adding fulvestrant to alisertib on objective tumor response rates in endocrine-resistant metastatic breast cancer.
-
JAMA Oncology
Original Investigation
January 1, 2023
Mary L. (Nora) Disis, MD; Katherine A. Guthrie, PhD; Ying Liu, PhD; Andrew L. Coveler, MD; Doreen M. Higgins, BSN; Jennifer S. Childs, MPH; Yushe Dang, PhD; Lupe G. Salazar, MD
JAMA Oncol. 2023; 9(1):71-78. doi: 10.1001/jamaoncol.2022.5143
This phase 1 nonrandomized clinical trial assesses the safety and immunogenicity of 3 doses (10, 100, and 500 μg) of a plasmid-based vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer.
-
JAMA Surgery
Original Investigation
November 1, 2022
Marie Osdoit, MD; Christina Yau, PhD; W. Fraser Symmans, MD; Judy C. Boughey, MD; Cheryl A. Ewing, MD; Ron Balassanian, MD; Yunn-Yi Chen, MD; Gregor Krings, MD; Anne M Wallace, MD; Somaye Zare, MD; Oluwole Fadare, MD; Rachael Lancaster, MD; Shi Wei, MD, PhD; Constantine V. Godellas, MD; Ping Tang, MD, PhD; Todd M Tuttle, MD; Molly Klein, MD; Sunati Sahoo, MD; Tina J. Hieken, MD; Jodi M. Carter, MD, PhD; Beiyun Chen, MD, PhD; Gretchen Ahrendt, MD; Julia Tchou, MD, PhD; Michael Feldman, MD; Eleni Tousimis, MD; Jay Zeck, MD; Nora Jaskowiak, MD; Husain Sattar, MD; Arpana M. Naik, MD; Marie Catherine Lee, MD; Marilin Rosa, MD; Laila Khazai, MD; Mara H. Rendi, MD; Julie E. Lang, MD; Janice Lu, MD; Ossama Tawfik, MD, PhD; Smita M. Asare, BS; Laura J. Esserman, MD; Rita A. Mukhtar, MD
JAMA Surg. 2022; 157(11):1034-1041. doi: 10.1001/jamasurg.2022.4118
This study examines the association of residual ductal carcinoma in situ in surgical specimens after neoadjuvant chemotherapy with breast cancer survival end points.
-
JAMA Oncology
Review
November 1, 2022
Aleix Prat, MD, PhD; Aditya Bardia, MD, MPH; Giuseppe Curigliano, MD, PhD; M. Elizabeth H. Hammond, MD; Sibylle Loibl, MD, PhD; Sara M. Tolaney, MD, MPH; Giuseppe Viale, MD
is active quiz
JAMA Oncol. 2022; 8(11):1676-1687. doi: 10.1001/jamaoncol.2022.4175
This review of current literature evaluates whether ERBB2 (formerly HER2) offers a potential therapeutic target in patients with ERBB2-low breast cancer.
-
JAMA Oncology
Original Investigation
August 1, 2022
Paolo Tarantino, MD; Qingchun Jin, MPH; Nabihah Tayob, PhD; Rinath M. Jeselsohn, MD; Stuart J. Schnitt, MD; Julie Vincuilla, BS; Tonia Parker, BS; Svitlana Tyekucheva, PhD; Tianyu Li, MS; Nancy U. Lin, MD; Melissa E. Hughes, MSc; Anna C. Weiss, MD; Tari A. King, MD; Elizabeth A. Mittendorf, MD, PhD; Giuseppe Curigliano, MD, PhD; Sara M. Tolaney, MD, MPH
free access
JAMA Oncol. 2022; 8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286
This cohort study investigates the association of ERBB-2 expression with clinicopathologic characteristics and prognosis among patients with ERBB2-low and ERBB2-0 breast cancer.
-
JAMA Network Open
Original Investigation
Oncology
September 15, 2022
Ombline de Calbiac, MD; Amélie Lusque, MS; Audrey Mailliez, MD; Thomas Bachelot, MD, PhD; Lionel Uwer, MD; Marie-Ange Mouret-Reynier, MD; George Emile, MD; Christelle Jouannaud, MD; Anthony Gonçalves, MD, PhD; Anne Patsouris, MD, PhD; Véronique Diéras, MD; Marianne Leheurteur, MD; Thierry Petit, MD, PhD; Paul Cottu, MD, PhD; Jean-Marc Ferrero, MD, PhD; Véronique D'Hondt, MD, PhD; Isabelle Desmoulins, MD; Joana Mourato-Ribeiro, MD; Anne-Laure Martin, PhD; Jean-Sébastien Frenel, MD, PhD
open access
JAMA Netw Open. 2022; 5(9):e2231170. doi: 10.1001/jamanetworkopen.2022.31170
This cohort study examines outcomes for patients with ERBB2-low metastatic breast cancer compared with those of patients with ERBB2-zero cancer.
-
JAMA Oncology
Original Investigation
September 1, 2022
Hee Kyung Ahn, MD; Sung Hoon Sim, MD, PhD; Koung Jin Suh, MD, MS; Min Hwan Kim, MD, PhD; Jae Ho Jeong, MD, PhD; Ji-Yeon Kim, MD, PhD; Dae-Won Lee, MD; Jin-Hee Ahn, MD, PhD; Heejung Chae, MD, PhD; Kyung-Hun Lee, MD, PhD; Jee Hyun Kim, MD, PhD; Keun Seok Lee, MD, PhD; Joo Hyuk Sohn, MD, PhD; Yoon-La Choi, MD, PhD; Seock-Ah Im, MD, PhD; Kyung Hae Jung, MD, PhD; Yeon Hee Park, MD, PhD
open access
JAMA Oncol. 2022; 8(9):1271-1277. doi: 10.1001/jamaoncol.2022.2310
This nonrandomized clinical trial aims to determine whether neoadjuvant atezolizumab, docetaxel, trastuzumab, and pertuzumab therapy for ERBB2-positive early breast cancer warrants continuation to the next phase.
-
JAMA Network Open
Original Investigation
Health Policy
September 29, 2022
Christopher R. Manz, MD, MSHP; Angela C. Tramontano, MPH; Hajime Uno, PhD; Ravi B. Parikh, MD, MPP; Justin E. Bekelman, MD; Deborah Schrag, MD, MPH
open access
JAMA Netw Open. 2022; 5(9):e2234161. doi: 10.1001/jamanetworkopen.2022.34161
This cohort study assesses the association between oncologists’ participation in Medicare’s Oncology Care Model and their use of novel cancer therapies for patients with cancer.
-
JAMA Oncology
Original Investigation
July 1, 2022
Pierre Heudel, MD, MSc, LLM; Jean-Sébastien Frenel, MD, PhD; Cécile Dalban; Fernando Bazan, MD; Florence Joly, MD, PhD; Antoine Arnaud, MD; Cyril Abdeddaim, MD; Annick Chevalier-Place, MD; Paule Augereau, MD; Patricia Pautier, MD, PhD; Camille Chakiba, MD; Benoit You, MD, PhD; Laurence Lancry-Lecomte, MD; Gwenaelle Garin, PhD; Virginie Marcel, PhD; Jean Jacques Diaz, PhD; Isabelle Treilleux, MD; David Pérol, MD; Michel Fabbro, MD; Isabelle Ray-Coquard, MD, PhD
free access
JAMA Oncol. 2022; 8(7):1001-1009. doi: 10.1001/jamaoncol.2022.1047
This randomized clinical trial of women with hormone receptor-positive recurrent or metastatic endometrial cancer examines adverse events and cancer recurrence among patients treated with vistusertib plus anastrozole and compares them with patients treated with anastrozole alone.
-
JAMA Oncology
Original Investigation
July 1, 2022
Jens-Uwe Blohmer, MD, PhD; Theresa Link, MD; Mattea Reinisch, MD; Marianne Just, MD; Michael Untch, MD; Oliver Stötzer, MD; Peter A. Fasching, MD; Andreas Schneeweiss, MD; Pauline Wimberger, MD, PhD; Sabine Seiler, MD; Jens Huober, MD; Marc Thill, MD, PhD; Christian Jackisch, MD, PhD; Kerstin Rhiem, MD; Christine Solbach, MD; Claus Hanusch, MD; Fenja Seither, MSc; Carsten Denkert, MD; Knut Engels, MD; Valentina Nekljudova, PhD; Sibylle Loibl, MD; GBG and AGO-B
free access
JAMA Oncol. 2022; 8(7):1010-1018. doi: 10.1001/jamaoncol.2022.1059
This randomized clinical trial assesses whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy increases the pathological complete response rate and which schedule is more effective.
-
JAMA Dermatology
Original Investigation
July 1, 2022
Hanxi Zhao, MD, PhD; Wanqi Zhu, MD; Xianguang Zhao, MD; Xiaolin Li, MD, PhD; Zhengbo Zhou, MD, PhD; Meizhu Zheng, MD; Xiangjiao Meng, MD, PhD; Lingling Kong, MD; Shuyu Zhang, MD, PhD; Dan He, MD, PhD; Ligang Xing, MD, PhD; Jinming Yu, MD, PhD
free access
JAMA Dermatol. 2022; 158(7):779-786. doi: 10.1001/jamadermatol.2022.1736
This randomized clinical trial assesses if epigallocatechin-3-gallate solution reduces the incidence of radiation-induced dermatitis in patients undergoing radiotherapy after breast cancer surgery.